Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

Leukemia Research

Volumn 36, Issue 10, 2012, Pages 1278-1282

  Smolej, Lukአ^a   Doubek, Michael ^b,c   Panovská, Anna ^c   Šimkovič, Martin ^a   Brychtová, Yvona ^b   Belada, David ^a   Motyčková, Monika ^a   Mayer, Jiří ^b,c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukemia; Corticosteroids; Dexamethasone; Refractory disease; Rituximab

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; INSULIN; RITUXIMAB;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE; GENE DELETION; HUMAN; HYPERGLYCEMIA; IMMUNOGLOBULIN VARIABLE HEAVY CHAIN GENE; INFECTION; INFLUENZA A (H1N1); LEUKEMIA REMISSION; LUNG ASPERGILLOSIS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OTITIS MEDIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYREXIA IDIOPATHICA; RECURRENT CANCER; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SINUSITIS; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROSEPSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 84865173645     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.005     Document Type: Article

References (18)

1. Dores G.M., Anderson W.F., Curtis R.E., Landgren O., Ostroumova E., Bluhm E.C., et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007, 139(5):809-819.
2. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2009, 602-609.
3. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
4. Robak T., Dmoszynska A., Solal-Celigny P., Warzocha K., Loscertales J., Catalano J., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1756-1765.
5. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010, 23(1):85-96.
6. Pettitt A.R. Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog. Leuk Lymphoma 2008, 49(10):1843-1845.
7. Thornton P.D., Hamblin M., Treleaven J.G., Matutes E., Lakhani A.K., Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999, 34(1-2):167-170.
8. Thornton P.D., Matutes E., Bosanquet A.G., Lakhani A.K., Grech H., Ropner J.E., et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003, 82(12):759-765.
9. Bowen D.A., Call T.G., Jenkins G.D., Zent C.S., Schwager S.M., Van Dyke D.L., et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007, 48(12):2412-2417.
10. Castro J.E., Sandoval-Sus J.D., Bole J., Rassenti L., Kipps T.J. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008, 22(November (11)):2048-2053.
11. Dungarwalla M., Evans S.O., Riley U., Catovsky D., Dearden C.E., Matutes E. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008, 93(3):475-476.
12. Pettitt A.R., Matutes E., Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006, 20(8):1441-1445.
13. Quinn J.P., Mohamedbhai S., Chipperfield K., Treacy M., D'Sa S., Nathwani A.C. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2008, 49(10):1995-1998.
14. Pileckyté R., Jurgutis M., Valceckiene V., et al. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011, 52:1055-1065.
15. Rituximab Summary of Product Characteristics, Rituximab Summary of Product Characteristics, European Medicines Agency Available online at [accessed on 13.07.12]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf.
16. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456.
17. Rose A.L., Smith B.E., Maloney D.G. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002, 100(5):1765-1773.
18. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99(10):3554-3561.